Patents Assigned to Erytech Pharma
-
Patent number: 11957724Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.Type: GrantFiled: September 30, 2020Date of Patent: April 16, 2024Assignee: ERYTECH PHARMAInventors: Flavie Pouillot, Hélène Blois
-
Patent number: 11458170Abstract: The invention relates to a pharmaceutical composition containing a PLP-dependent enzyme and optionally its cofactor, pyridoxal phosphate (PLP), and/or a phosphate or non-phosphate precursor of PLP, its use as a drug, its production method and a therapeutic treatment method related to it. The pharmaceutical composition comprises erythrocytes and a pharmaceutically acceptable vehicle, the erythrocytes encapsulating the PLP-dependent enzyme. The PLP-dependent enzyme may be methioninase, tyrosine phenol-lyase, tyrosine aminotransferase or cystathionine beta-synthase.Type: GrantFiled: September 22, 2020Date of Patent: October 4, 2022Assignee: ERYTECH PHARMAInventors: Yann Godfrin, Vanessa Bourgeaux, Fabien Gay, Thomas Cortese
-
Patent number: 11273210Abstract: The present invention is related to arginine deiminase encapsulated into erythrocytes for use in therapy. It is in particular related to the use thereof in treating arginase-1 deficiency. Also, it relates to novel pharmaceutical compositions comprising arginine deiminase from M. arginini encapsulated into erythrocytes and the use thereof in treating diseases that may benefit from arginine depletion, such as arginine dependent cancers, in particular arginine-auxotrophic cancers, and arginase-1 deficiency.Type: GrantFiled: June 29, 2018Date of Patent: March 15, 2022Assignee: ERYTECH PHARMAInventors: Emmanuelle Dufour, Manuel Blanc, Aurélien Meyzaud
-
Patent number: 11141468Abstract: The invention is related to a new method for treating liquid and solid cancers, in a mammal, including human, wherein methioninase is administered before asparaginase. The invention also encompasses the use of a dietary methionine deprivation, possibly combined with methioninase administration, in advance of asparaginase treatment. Methioninase and asparaginase may be used in particular under free form, pegylated form or encapsulated into erythrocytes.Type: GrantFiled: January 2, 2017Date of Patent: October 12, 2021Assignee: ERYTECH PHARMAInventors: Karine Aguera, Willy Berlier, Fabien Gay, Yann Godfrin
-
Patent number: 10780151Abstract: The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumour cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of an immune complex with an immunoglobulin, in particular IgG, which recognizes an epitope at the surface of the red blood cells, and/or be heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells. As a variant, the red blood cells may be xenogenic red blood cells. The invention also relates to a therapeutic especially anti-tumour vaccine containing such a composition.Type: GrantFiled: April 24, 2018Date of Patent: September 22, 2020Assignee: Erytech PharmaInventors: Yann Godfrin, Alice Banz
-
Patent number: 10780126Abstract: The invention relates to a pharmaceutical kit containing a) an injectable suspension of erythrocytes encapsulating a pyridoxal phosphate (PLP)-dependent enzyme and b) a non-phosphate PLP precursor. The invention further relates to methods of producing component(s) of the kit and to therapeutic treatment methods related to the kit. The PLP-dependent enzyme may be a methioninase, a tyrosine phenol-lyase, a tyrosine aminotransferase or a cystathionine beta-synthase.Type: GrantFiled: August 13, 2018Date of Patent: September 22, 2020Assignee: ERYTECH PHARMAInventors: Yann Godfrin, Vanessa Bourgeaux, Fabien Gay, Thomas Cortese
-
Patent number: 10286008Abstract: A method for obtaining a stabilized suspension of red blood cells encapsulating an active ingredient, from resealed RBCs incorporating the active ingredient, the method comprising the incubation of the resealed RBCs in an incubation solution at an osmolality of no less than 280 m Osmol/kg, for a time of 30 minutes or more, the incubation solution being a solution that does not contain an agent which is denaturating for the RBC membrane, the liquid medium is then removed from the incubated suspension and the RBCs obtained are placed in suspension in a solution allowing the injection of the suspension in a patient. The suspensions obtained are particularly characterized by an extracellular haemoglobin level maintained at 0.5 or lower, in particular 0.2 g/dl or lower and/or a hemolysis rate maintained at 2 or less, in particular 1% or less, at 72 h after placing in suspension in a preservation solution and at a temperature of between 2 and 8° C.Type: GrantFiled: May 7, 2014Date of Patent: May 14, 2019Assignee: ERYTECH PHARMAInventors: Yann Godfrin, Vanessa Bourgeaux, Jérôme Bailly
-
Patent number: 10273444Abstract: A lysis/resealing process for preparing erythrocytes containing active ingredient is provided comprising placing a globular concentrate in suspension in an isotonic solution having a haematocrit level which is equal to or greater than 65%, with refrigeration at 1 to 8° C.; measuring the osmotic fragility based on a sample of erythrocytes from that same globular concentrate, preferably on a sample of the suspension; lysis and internalization procedure of the active ingredient, inside the same chamber, at a temperature maintained at 1 to 8° C., comprising allowing the erythrocyte suspension having a haematocrit level equal to or greater than 65% and a hypotonic lysis solution which is refrigerated at 1 to 8° C., to circulate in a dialysis cartridge; the lysis parameters being adjusted in accordance with the osmotic fragility previously measured; and resealing in a second chamber at a temperature of from 30 to 40° C. by means of a hypertonic solution.Type: GrantFiled: November 26, 2013Date of Patent: April 30, 2019Assignee: ERYTECH PHARMAInventor: Yann Godfrin
-
Patent number: 10046009Abstract: The invention relates to a pharmaceutical composition containing a PLP-dependent enzyme and optionally its cofactor, pyridoxal phosphate (PLP), and/or a phosphate or non-phosphate precursor of PLP, its use as a drug, its production method and a therapeutic treatment method related to it. The pharmaceutical composition comprises erythrocytes and a pharmaceutically acceptable vehicle, the erythrocytes encapsulating the PLP-dependent enzyme. The PLP-dependent enzyme may be methioninase, tyrosine phenol-lyase, tyrosine aminotransferase or cystathionine beta-synthase.Type: GrantFiled: February 12, 2015Date of Patent: August 14, 2018Assignee: ERYTECH PHARMAInventors: Yann Godfrin, Vanessa Bourgeaux, Fabien Gay, Thomas Cortese
-
Patent number: 9968663Abstract: Use of erythrocytes containing arginine deirainase for the preparation of a medicinal product for lowering the plasma concentration of arginine in vivo. The use relates in particular to the treatment of arginine-dependent tumors, such as hepatocarcinoma and malignant melanoma, or inhibition of the synthesis of nitric oxide, and the prevention and/or treatment of septic shock.Type: GrantFiled: July 31, 2015Date of Patent: May 15, 2018Assignee: ERYTECH PHARMAInventors: Yann Godfrin, Pierre-Olivier Goineau
-
Patent number: 9950049Abstract: The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumor cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of an immune complex with an immunoglobulin, in particular IgG, which recognizes an epitope at the surface of the red blood cells, and/or be heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells. As a variant, the red blood cells may be xenogenic red blood cells. The invention also relates to a therapeutic especially anti-tumor vaccine containing such a composition.Type: GrantFiled: May 13, 2016Date of Patent: April 24, 2018Assignee: ERYTECH PHARMAInventors: Yann Godfrin, Alice Banz
-
Patent number: 9580739Abstract: Method of in vitro measurement of the presence of factors that are able to neutralize asparaginase activity in a sample of blood, plasma, serum or derived medium that may contain asparaginase neutralizing factors, obtained from a patient, comprising mixing of said sample with asparaginase, incubation of said mixture, then measurement of the residual asparaginase activity in the mixture and determination or quantification of the presence of said neutralizing factors. Method for predicting the efficacy of a treatment with asparaginase.Type: GrantFiled: September 18, 2014Date of Patent: February 28, 2017Assignee: ERYTECH PHARMAInventor: Yann Godfrin
-
Patent number: 9364504Abstract: The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumor cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of an immune complex with an immunoglobulin, in particular IgG, which recognizes an epitope at the surface of the red blood cells, and/or be heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells. As a variant, the red blood cells may be xenogenic red blood cells. The invention also relates to a therapeutic especially anti-tumor vaccine containing such a composition.Type: GrantFiled: August 8, 2008Date of Patent: June 14, 2016Assignee: ERYTECH PHARMAInventors: Yann Godfrin, Alice Banz
-
Publication number: 20160095884Abstract: A method for obtaining a stabilised suspension of red blood cells encapsulating an active ingredient, from resealed RBCs incorporating the active ingredient, the method comprising the incubation of the resealed RBCs in an incubation solution at an osmolality of no less than 280 m Osmol/kg, for a time of 30 minutes or more, the incubation solution being a solution that does not contain an agent which is denaturating for the RBC membrane, the liquid medium is then removed from the incubated suspension and the RBCs obtained are placed in suspension in a solution allowing the injection of the suspension in a patient. The suspensions obtained are particularly characterized by an extracellular haemoglobin level maintained at 0.5 or lower, in particular 0.2 g/dl or lower and/or a haemolysis rate maintained at 2 or less, in particular 1% or less, at 72 h after placing in suspension in a preservation solution and at a temperature of between 2 and 8° C.Type: ApplicationFiled: May 7, 2014Publication date: April 7, 2016Applicant: ERYTECH PHARMAInventors: Yann GODFRIN, Vanessa BOURGEAUX, Jérôme BAILLY
-
Patent number: 9125876Abstract: Use of erythrocytes containing arginine deirainase for the preparation of a medicinal product for lowering the plasma concentration of arginine in vivo. The use relates in particular to the treatment of arginine-dependent tumors, such as hepatocarcinoma and malignant melanoma, or inhibition of the synthesis of nitric oxide, and the prevention and/or treatment of septic shock.Type: GrantFiled: April 25, 2006Date of Patent: September 8, 2015Assignee: ERYTECH PHARMAInventors: Yann Godfrin, Pierre-Olivier Goineau
-
Patent number: 8974802Abstract: The invention relates to a suspension of red corpuscles encapsulating asparaginase as a medicament for treating pancreatic cancer. It in particular concerns a therapeutic composition or medicament intended for the treatment of pancreatic cancer, containing an effective quantity of such a suspension of red corpuscles.Type: GrantFiled: December 24, 2008Date of Patent: March 10, 2015Assignee: Erytech PharmaInventors: Emmanuelle-Cécile Dufour, Yann Godfrin
-
Patent number: 8852880Abstract: Method of in vitro measurement of the presence of factors that are able to neutralize asparaginase activity in a sample of blood, plasma, serum or derived medium that may contain asparaginase neutralizing factors, obtained from a patient, comprising mixing of said sample with asparaginase, incubation of said mixture, then measurement of the residual asparaginase activity in the mixture and determination or quantification of the presence of said neutralizing factors. Method for predicting the efficacy of a treatment with asparaginase.Type: GrantFiled: November 6, 2009Date of Patent: October 7, 2014Assignee: Erytech PharmaInventor: Yann Godfrin
-
Publication number: 20140154797Abstract: A lysis/resealing process for preparing erythrocytes containing active ingredient is provided comprising placing a globular concentrate in suspension in an isotonic solution having a haematocrit level which is equal to or greater than 65%, with refrigeration at 1 to 8° C.; measuring the osmotic fragility based on a sample of erythrocytes from that same globular concentrate, preferably on a sample of the suspension; lysis and internalisation procedure of the active ingredient, inside the same chamber, at a temperature maintained at 1 to 8° C., comprising allowing the erythrocyte suspension having a haematocrit level equal to or greater than 65% and a hypotonic lysis solution which is refrigerated at 1 to 8° C., to circulate in a dialysis cartridge; the lysis parameters being adjusted in accordance with the osmotic fragility previously measured; and resealing in a second chamber at a temperature of from 30 to 40° C. by means of a hypertonic solution.Type: ApplicationFiled: November 26, 2013Publication date: June 5, 2014Applicant: ERYTECH PHARMAInventor: Yann GODFRIN
-
Patent number: 8617840Abstract: Lysis/resealing process for preparing erythrocytes which contain an active ingredient (e.g. aspariginase or inositol hexaphosphate), the process comprising the following steps: (1) placing a globular concentrate in suspension in an isotonic solution having a haematocrit level which is equal to or greater than 65%, with refrigeration at from +1 to +8° C., (2) measuring the osmotic fragility based on a sample of erythrocytes from that same globular concentrate, preferably on a sample of the suspension obtained in step (1), (3) lysis and internalization procedure of the active ingredient, inside the same chamber, at a temperature which is constantly maintained at from +1 to +8° C., comprising allowing the erythrocyte suspension having a haematocrit level which is equal to or greater than 65% and a hypotonic lysis solution which is refrigerated at from +1 to +8° C.Type: GrantFiled: August 4, 2005Date of Patent: December 31, 2013Assignee: Erytech PharmaInventor: Yann Godfrin
-
Publication number: 20120009140Abstract: The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumour cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of an immune complex with an immunoglobulin, in particular IgG, which recognizes an epitope at the surface of the red blood cells, and/or be heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells. As a variant, the red blood cells may be xenogenic red blood cells. The invention also relates to a therapeutic especially anti-tumour vaccine containing such a composition.Type: ApplicationFiled: August 8, 2008Publication date: January 12, 2012Applicant: Erytech PharmaInventors: Yann Godfrin, Alice Banz